Opthea (ASX:OPT) — Material Events
ASX:OPT · 7 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Opthea’s $340M Profit Fuels Bold Pivot to Rare Lung Disease TherapyHigh
Opthea reports A$339.9M profit, pivots to rare lung disease treatment with OPT-302
2 Mar 2026
·Appendix 4D Half-year report
·Unexpected
·85
Opthea Returns to ASX with Focused OPT-302 Program for Rare Lung Disease LAMMedium
Opthea reinstated to ASX, advances OPT-302 development for rare lung disease LAM
3 June 2026
·Reinstatement and Development Program Update
·75
Opthea Reboots with OPT-302 to Target Rare Lung Disease LAMMedium
Opthea refocuses on rare lung disease LAM with OPT-302, targets ASX reinstatement in 2026
17 Dec 2025
·Investor Update
·75
Opthea Secures A$10.8M Boost for Sozinibercept R&D ProgressMedium
Opthea Receives A$10.8M R&D Tax Incentive for Sozinibercept Development
6 Oct 2025
·ASX Announcement
·70
Which Stocks Are Moving in the S&P/ASX September 2025 Rebalance?Medium
S&P/ASX Indices Quarterly Rebalance Effective September 22, 2025
5 Sept 2025
·Index Rebalance Announcement
·70
Opthea Cuts Costs, Settles Major Liability, and Eyes Strategic ResetMedium
Opthea simplifies operations, settles DFA liability, and advances strategic review with improved cash position
31 Oct 2025
·Quarterly Activity Report and Appendix 4C
·70
No articles in this tier for the last 12 months.
Market Mentions
3
- appeared in market wrap coverage
These are market wrap articles where Opthea (ASX:OPT) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 23 (1 June -> 5 June) 2026
6 June 2026
Market Wrap - Week 10 (2 Mar -> 6 Mar) 2026
7 Mar 2026
Healthcare Wrap - Week 10 (2 Mar -> 6 Mar) 2026
7 Mar 2026